Osmind, San Francisco, CA (2025)

10/10/2025

Mental healthcare takes a village. We need each other. From supportive communities and environments that foster well-being, to innovative treatments for those facing treatment-resistant depression.

Today, we’re grateful for the researchers asking hard questions, the clinicians showing up every day, and the pioneers trying new approaches when the old ones aren’t enough. You’re making a difference.

Check on your loved ones. Check in with yourself. We’re here for each other.

10/10/2025

Mental healthcare takes a village. We need each other. From supportive communities and environments that foster well-being, to innovative treatments for those facing treatment-resistant depression.

Today, we're grateful for the researchers asking hard questions, the clinicians showing up every day, and the pioneers trying new approaches when the old ones aren't enough. You're making a difference.

Check on your loved ones. Check in with yourself. We're here for each other.

10/10/2025

"The cat's out of the bag. I don't see a world in future psychiatry that's just medicine and therapy."

Martha B. Koo, M.D., LFAPA, FASAM, FCTMSS doesn't mince words about where psychiatry is headed. After 15 years building TMS programs, she sees resistance to brain stimulation like refusing to join psychiatry's tomorrow.

"It's no different than deciding I'm putting every patient on Prozac and staying in the eighties," she says. "You don't want to practice medicine in the olden days."

10/08/2025

🎯 Two can't-miss live events (VNS, and KIT for PTSD) coming up in the Osmind Psychiatry Collective:

🗓️Oct 9, 11:00-11:30 AM PDT
Vagus Nerve Stimulation (VNS) in Psychiatry with Martha B. Koo, M.D., LFAPA, FASAM, FCTMSS.

As Dr. Koo's practice launches VNS services this November, join the discussion on this neuromodulation therapy for treatment-resistant patients. Clinical pearls, patient selection, and implementation strategies.

🗓️Oct 22, 9:00-9:30 AM PDT
Ketamine for PTSD: New Real-World Research with L. Alison McInnes MD, MS.

Examine new research showing:
•77% response rates in 1,300+ PTSD patients.
•Get practical implementation strategies, optimal dosing protocols (0.6-0.8 mg/kg), and patient selection insights.

Both events feature:
✅ Open discussion format—no slides, just real conversation
✅ Peer-driven learning with expert insights
✅ Live Q&A to get your questions answered

RSVP now below!

10/06/2025

We're honored that Osmind has been selected from thousands of companies globally as a finalist for:

The Digital Health Hub Foundation - Digital Health Awards

in the Best in Class track - Mental and Behavioral Health category!

These awards honor outstanding health technologies and innovations dramatically transforming healthcare.

This recognition underscores Osmind's commitment to advancing life-saving mental health treatments. Thank you for your continued support!

10/02/2025

Here's what you missed the last two weeks in the Osmind Psychiatry Collective, the online community where forward thinking clinicians go to learn, grow their practice, and connect:

🍄 First real-world psilocybin data from legal U.S. services: Bendable Therapy and Osmind presented breakthrough research from Oregon's program at Psych Congress 2025. The study examined real-world participants with complex populations that clinical trials often exclude.

🤖 September AI theme wrap-up & poll: Honest community feedback on AI excitment and limitations in psychiatry. Members shared candid takes on where AI falls short of the hype and realistic expectations for mental health applications.

📈 October theme: Patient acquisition strategies: All month we’re discussing practice growth tactics. Optimize your digital presence, referral systems, and adapt to evolving patient expectations.

🔔 RSVP for upcoming live event on VNS with Martha B. Koo, M.D., LFAPA, FASAM, FCTMSS: As her practice prepares to launch VNS services this November, she'll share implementation strategies, patient selection insights, and clinical pearls in an open discussion format.

10/01/2025

Most psychiatry practices lose revenue to billing inefficiencies, but don't realize it until cash flow becomes a crisis. Here's your 101 guide to Revenue Cycle Management (no MBA required).

Learn:

•Which metrics actually matter (and what healthy ranges look like)

•Where revenue typically leaks in psychiatry billing

•When to handle billing in-house vs. partner with specialists

Make informed decisions about your practice finances:https://www.osmind.org/blog/psychiatry-revenue-cycle-management

09/30/2025

"I'm good, but I'm not my true full self."

Dr. Martha B. Koo, M.D., LFAPA, FASAM, FCTMSS heard this from her own therapy patients after placing a simple TMS brochure in her waiting room.

These were patients she considered stable on medication and therapy.

"You lose perspective. I never met those people at their 100%..You see how people pop with TMS," Koo explains. "They come to life with so much more color!"

Interventions like TMS can shift how your benchmark for treatment goals. Maybe "stable" isn't the same as "thriving."

Full "Psychiatry Tomorrow" episode available on our blog (link in comments below), Spotify, or Apple Podcasts!

09/24/2025

Ketamine + TMS + Spravato: What's working in real practice?

If you're offering ketamine as a treatment, you've probably wondered about combining it with TMS or Spravato. The data is promising, but practical questions are endless: patient selection, sequencing, what actually works in your clinic setup.

Join William Sauvé, MD (Osmind CMO) and David Feifel, MD, PhD (Kadima Neuropsychiatry Institute Founder) for a candid discussion hosted by Psychedelic Medicine Association about what they're seeing work—and what isn't.

Here's what you'll learn:

•Appropriate patient populations and selection criteria for adjunctive therapy

•Current evidence regarding the efficacy and safety of combining or sequencing these treatments

•Mechanisms of action and clinical indications for ketamine, TMS, and esketamine (Spravato)

•Best practices for integrating these modalities into individualized treatment plans for patients with mood disorders

🗓️Tuesday, September 30th • 5 PM Pacific / 8 PM Eastern

This is a great opportunity to learn practical integration strategies and get your questions answered directly by the experts.

(Link to register in comments)

09/23/2025

Psych Congress 2025 Recap: Psilocybin Real-World Evidence and Digital Psychiatry

Just wrapped four days in San Diego for Psych Congress. Wonderful to connect and share new research.

Some highlights:

➡️ Our Chief Medical Officer, William Sauvé, MD, led a session on digital psychiatry, covering practical tools and strategies for clinicians integrating technology into their practice. The focus was on Osmind’s in-workflow AI for patient identification and treatment selection, integrated with downstream workflow automation.

➡️ Bendable Therapy and Osmind presented the first real-world evidence from Oregon’s legal psilocybin program through two posters, in conjunction with UCSF’s Robin Carhart-Harris.

Key finding: Real-world participants showed meaningful improvements in depression, anxiety, and well-being scores—validating that clinical trial results translate to diverse patient populations.

➡️ Big shoutout to Osmind medical advisor, Brittany Albright MD, MPH, who gave many amazing talks, including a heartfelt tribute to Dr. Maletic, reminding clinicians, “We can be the medicine our patients need.”

Dr. Albright also capped the conference off helping bring interventional psychiatry to more clinicians. Her work continues to drive the field forward!

Cheers to more conversations on how we can use data, technology, and research to help people benefit from innovative mental health treatments!

09/19/2025

Last week, a group of us gathered in San Francisco to reflect on all the progress we’ve made on our mission to empower clinicians and researchers to bring innovative mental health treatments to patients who need them most.

What a nice surprise this week to have TIME recognize Osmind as one of the World’s Top Health Tech Companies of 2025!

But what struck us the most during our SF conversations were the stories our team shared about the clinicians we serve—psychiatrists pioneering novel treatments for depression, researchers advancing psychedelic medicine, practices transforming their operations with our platform.

At Osmind, we’re not just building healthcare technology. We’re empowering the innovators in psychiatry who are redefining what’s possible in mental health treatment, ensuring breakthrough therapies reach the patients who need them most.

Thank you TIME and thank you to all the mental health innovators that inspire us every day!

09/19/2025

Last week, a group of us gathered in San Francisco to reflect on all the progress we've made on our mission to empower clinicians and researchers to bring innovative mental health treatments to patients who need them most.

What a nice surprise this week to have TIME recognize Osmind as one of the World's Top Health Tech Companies of 2025!

But what struck us the most during our SF conversations were the stories our team shared about the clinicians we serve—psychiatrists pioneering novel treatments for depression, researchers advancing psychedelic medicine, practices transforming their operations with our platform.

At Osmind, we're not just building healthcare technology. We're empowering the innovators in psychiatry who are redefining what's possible in mental health treatment, ensuring breakthrough therapies reach the patients who need them most.

Thank you TIME and thank you to all the mental health innovators that inspire us every day!

Osmind

10/10/2025

10/10/2025

10/10/2025

10/08/2025

10/06/2025

10/02/2025

10/01/2025

09/30/2025

09/24/2025

09/23/2025

09/19/2025

09/19/2025

Address

Website

Alerts

Contact The Practice

Shortcuts

Share

Category